← Leaderboards
Paula M Cannon
Scripps Research Institute, The
$25,669,125
Attributed
$38,663,099
Total exposure
24
Grants
19
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $10.9M · FY2005–25$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$69,773,521 · 27
By mechanism
U19$32,749,471 · 10
UM1$15,031,786 · 1
R01$10,351,916 · 4
P01$4,925,094 · 4
U54$2,748,988 · 2
R33$1,485,000 · 1
Top collaborators
- Hans-Peter Kiem12 shared
- Adi Barzel4 shared
- James Even Voss4 shared
- Sumit K Chanda3 shared
- Jonathan Karn3 shared
- Rafick-Pierre Sekaly3 shared
Most similar at Scripps Research Institute, The
Same institution · by research overlap
- Robert F Garry$57,098,933
- Sumit K Chanda$45,754,771
- Kathryn Marie Hastie$1,015,388
- Jeffrey Ernest Lee$98,185
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsViralVirusBaseProgramsEngineeringHiv InfectionsCollaborationsSitePathway InteractionsT-LymphocyteGene TherapyGenesHiv-1Humanized MouseNonhuman PrimateIn VivoMouse ModelReagentMacacaSafetyMediatingTechnologyInfection
Grant awards (81)
Reversing Immune Dysfunction for HIV-1 Eradication$5,028,890
UM1 · FY2025 · AI
In vivo cell engineering for HIV cure.$3,693,667
P01 · FY2025 · HL · contact PI
Nuclear receptor regulation of epigenetic mechanisms regulating HIV CNS latency$718,553
R01 · FY2025 · MH
In vivo engineering of B cells for the secretion of HIV broadly neutralizing antibodies$700,174
R01 · FY2025 · AI
B cells as boostable factories for HIV inhibition$516,986
P01 · FY2025 · HL · contact PI
Administrative Core$259,183
P01 · FY2025 · HL · contact PI
Reversing Immune Dysfunction for HIV-1 Eradication$5,001,089
UM1 · FY2024 · AI
Novel hematopoietic stem cell engineering and transplantation approaches for HIV cure$2,334,036
U19 · FY2024 · HL · contact PI
In vivo engineering of B cells for the secretion of HIV broadly neutralizing antibodies$733,631
R01 · FY2024 · AI
Nuclear receptor regulation of epigenetic mechanisms regulating HIV CNS latency$724,325
R01 · FY2024 · MH
Combination gene editing for local and systemic HIV resistance$449,390
U19 · FY2024 · HL · contact PI
Administrative Core$295,228
U19 · FY2024 · HL · contact PI
Novel hematopoietic stem cell engineering and transplantation approaches for HIV cure$3,528,529
U19 · FY2023 · HL · contact PI
Nuclear receptor regulation of epigenetic mechanisms regulating HIV CNS latency$745,179
R01 · FY2023 · MH
In vivo engineering of B cells for the secretion of HIV broadly neutralizing antibodies$738,581
R01 · FY2023 · AI
Combination gene editing for local and systemic HIV resistance$519,106
U19 · FY2023 · HL · contact PI
Administrative Core$345,708
U19 · FY2023 · HL · contact PI
Gene edited B cells to co-express CNS-targeted antibodies$247,500
R21 · FY2023 · MH · contact PI
Novel hematopoietic stem cell engineering and transplantation approaches for HIV cure$2,978,475
U19 · FY2022 · HL · contact PI
In vivo engineering of B cells for the secretion of HIV broadly neutralizing antibodies$645,746
R01 · FY2022 · AI
Combination gene editing for local and systemic HIV resistance$493,786
U19 · FY2022 · HL · contact PI
Administrative Core$335,893
U19 · FY2022 · HL · contact PI
Gene edited B cells to co-express CNS-targeted antibodies$206,250
R21 · FY2022 · MH · contact PI
Reversing Immune Dysfunction for HIV-1 Eradication$5,001,807
UM1 · FY2021 · AI
Novel hematopoietic stem cell engineering and transplantation approaches for HIV cure$2,658,178
U19 · FY2021 · HL · contact PI
Targeted inactivation of HIV in CNS reservoirs$732,093
R01 · FY2021 · MH · contact PI
Combination gene editing for local and systemic HIV resistance$396,477
U19 · FY2021 · HL · contact PI
Administrative Core$242,979
U19 · FY2021 · HL · contact PI
Novel hematopoietic stem cell engineering and transplantation approaches for HIV cure$3,085,105
U19 · FY2020 · HL · contact PI
Targeted inactivation of HIV in CNS reservoirs$735,090
R01 · FY2020 · MH · contact PI
Administrative Core$514,185
U19 · FY2020 · AI · contact PI
Combination gene editing for local and systemic HIV resistance$514,184
U19 · FY2020 · AI · contact PI
Next Generation HSC Gene Therapy for HIV Control and Eradication$2,529,095
U19 · FY2019 · HL · contact PI
Targeted inactivation of HIV in CNS reservoirs$737,286
R01 · FY2019 · MH · contact PI
Admin Core$169,147
U19 · FY2019 · HL · contact PI
Precision gene editing for HIV gene therapy$68,728
U19 · FY2019 · HL · contact PI
Next Generation HSC Gene Therapy for HIV Control and Eradication$2,529,095
U19 · FY2018 · HL · contact PI
Targeted inactivation of HIV in CNS reservoirs$740,473
R01 · FY2018 · MH · contact PI
HIV-specific nucleases to reservoir cells$495,000
R33 · FY2018 · AI · contact PI
Admin Core$169,147
U19 · FY2018 · HL · contact PI
Precision gene editing for HIV gene therapy$68,728
U19 · FY2018 · HL · contact PI
Next Generation HSC Gene Therapy for HIV Control and Eradication$2,514,507
U19 · FY2017 · HL · contact PI
Targeted inactivation of HIV in CNS reservoirs$759,286
R01 · FY2017 · MH · contact PI
HIV-specific nucleases to reservoir cells$495,000
R33 · FY2017 · AI · contact PI
Admin Core$169,147
U19 · FY2017 · HL · contact PI
Next Generation HSC Gene Therapy for HIV Control and Eradication$2,514,507
U19 · FY2016 · HL · contact PI
HIV-specific nucleases to reservoir cells$495,000
R33 · FY2016 · AI · contact PI
Admin Core$169,147
U19 · FY2016 · HL · contact PI
Next Generation HSC Gene Therapy for HIV Control and Eradication$2,516,838
U19 · FY2015 · HL · contact PI
Precision gene editing for HIV gene therapy$228,390
U19 · FY2015 · HL · contact PI
Next Generation HSC Gene Therapy for HIV Control and Eradication$228,390
U19 · FY2015 · HL · contact PI
HIV-specific nucleases to reservoir cells$225,333
R21 · FY2015 · AI · contact PI
Admin Core$183,346
U19 · FY2015 · HL · contact PI
HIV-specific nucleases to reservoir cells$205,208
R21 · FY2014 · AI · contact PI
Targeting the Entry Pathway of New World Arenaviruses for Anitviral Threraputics$318,333
U54 · FY2013 · AI · contact PI
Targeting the Entry Pathway of New World Arenaviruses for Anitviral Threraputics$303,049
U54 · FY2012 · AI · contact PI
Targeting the Entry Pathway of New World Arenaviruses for Anitviral Threraputics$366,562
U54 · FY2011 · AI · contact PI
Targeting the Entry Pathway of New World Arenaviruses for Anitviral Threraputics$352,054
U54 · FY2010 · AI · contact PI
Understanding how HIV-1 Vpu and HIV-2 Env stimulate virus release$282,462
R01 · FY2010 · AI · contact PI
Understanding how HIV-1 Vpu and HIV-2 Env stimulate virus release$84,457
R01 · FY2010 · AI · contact PI
Understanding how HIV-1 Vpu and HIV-2 Env stimulate virus release$361,017
R01 · FY2009 · AI · contact PI
Targeting the Entry Pathway of New World Arenaviruses for Anitviral Threraputics$351,908
U54 · FY2009 · AI · contact PI
Retroviral Vectors for Safe and Efficacious Gene Therapy$366,732
R42 · FY2008 · RR · contact PI
Receptor Use by Pathogenic New World Arenaviruses$271,081
U54 · FY2008 · AI · contact PI
Understanding how HIV-1 Vpu and HIV-2 Env stimulate virus release$262,546
R01 · FY2008 · AI · contact PI
Understanding how HIV-1 Vpu and HIV-2 Env stimulate virus release$68,385
R01 · FY2008 · AI · contact PI
Retroviral Vectors for Safe and Efficacious Gene Therapy$329,438
R42 · FY2007 · RR · contact PI
Receptor Use by Pathogenic New World Arenaviruses$270,471
U54 · FY2007 · AI · contact PI
Understanding how HIV-1 Vpu and HIV-2 Env stimulate virus release$267,632
R01 · FY2007 · AI · contact PI
Core C-- Vectors$117,748
P01 · FY2007 · HL · contact PI
Understanding how HIV-1 Vpu and HIV-2 Env stimulate virus release$315,000
R01 · FY2006 · AI · contact PI
Receptor Use by Pathogenic New World Arenaviruses$266,791
U54 · FY2006 · AI · contact PI
Retroviral Vectors for Safe and Efficacious Gene Therapy$209,395
R42 · FY2006 · RR · contact PI
Core C-- Vectors$115,712
P01 · FY2006 · HL · contact PI
Retroviral Vectors for Safe and Efficacious Gene Therapy$96,511
R42 · FY2006 · RR · contact PI
Receptor Use by Pathogenic New World Arenaviruses$248,739
U54 · FY2005 · AI
Core C-- Vectors$112,539
P01 · FY2005 · HL
ENTRY PATHWAY OF NEW WORLD CLADE B ARENAVIRUSES$223,200
R21 · FY2004 · AI
Retroviral Vectors for Safe and Efficacious Gene Therapy$148,499
R41 · FY2004 · RR
Core C-- Vectors$109,259
P01 · FY2004 · HL
ENTRY PATHWAY OF NEW WORLD CLADE B ARENAVIRUSES$223,200
R21 · FY2003 · AI